Everything below concerns analytical methods. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Lean MASLD affects between 10 and 20% of Americans and Europeans, and approximately 25% of Asians, although some countries have a higher incidence (e.g., India has a very high proportion of lean MASLD and almost no obese MASLD). PNPLA3 may be relevant for the progression of MASLD in lean people. Thus, people with MASLD deserve consideration for treatment regardless of the presence or absence of obesity. In children ages 1 to 19, the prevalence was found to be approximately 8% in the general population, up to 34% in studies with data from child obesity clinics. The majority of cryptogenic cirrhosis is believed to be due to MASH. MASFLD prevalence is expected to increase steadily, from 25% in 2018 to a projected 33.5% of people with MASLD globally in 2030, and from 20% to a projected 27% of those with MASLD will progress to MASH.
=== Insomnia === Low-dose trazodone is used off-label in the treatment of insomnia and is considered to be effective and safe for this indication. It may also be used to treat antidepressant-related insomnia. Trazodone was the second-most prescribed agent for insomnia in the early 2000s even though most studies of trazodone for the treatment of sleep disturbances have been in depressed individuals. Systematic reviews and meta-analyses published in the late 2010s, including a Cochrane review, found low-dose trazodone to be an effective medication for short-term treatment of insomnia in both depressed and euthymic people. Trazodone slightly improves subjective sleep quality (SMDTooltip standardized mean difference = –0.34 to –0.41) and reduces the number of nighttime awakenings (MD = –0.31, SMD = –0.51), on average. Conversely, it does not appear to affect sleep onset, total sleep time, time awake after sleep onset, or sleep efficiency. It appears to increase deep sleep—in contrast to certain other hypnotics. The quality of evidence of trazodone for short-term treatment of insomnia was rated as low to moderate. There is no evidence available at present to inform the long-term use of trazodone in the treatment of insomnia. The benefits of trazodone for insomnia must be weighed against potential adverse effects, such as morning grogginess, daytime sleepiness, cognitive and motor impairment, and postural hypotension, among others. Quality safety data on the use of trazodone as a sleep aid are currently lacking.
=== Sulfation of calcium oxides === Sulfation is a process used to remove "sulfur" from the combustion of fossil fuels. The goal is to minimize the pollution by the combusted gases. Combustion of sulfur-containing fuels releases sulfur dioxide, which, in the atmosphere, oxidizes to the equivalent of sulfuric acid, which is corrosive. To minimize the problem, the combustion is often conducted in the presence of calcium oxide or calcium carbonate, which, directly or indirectly, bind sulfur dioxide and some oxygen to give calcium sulfite. The net reaction is:
This acquisition increased the total number of 7-Eleven stores in the US and Canada to nearly 9800. Following the purchase, the Oklahoma 7-Elevens were fully integrated into national branding, marketing, and loyalty campaigns. In April 2021, 7-Eleven launched the "Take it to Eleven" ad campaign. The slogan was partially inspired by the chain's name, but also the term "up to eleven" made popular in the film This is Spinal Tap. The slogan was only for the main 7-Eleven brand and not A-Plus or Stripes. By summer 2021, the company had installed just a few electric vehicle charging stations, but announced plans to expand considerably, with a target of 250 DC fast-charging locations in the U.S. and Canada by the end of 2022, starting with four states (California, Colorado, Florida and Texas). Less than two years later, in mid-March 2023, 7-Eleven announced plans for 7Charge, "its new, proprietary EV charging network and app", promoting the Android and iOS mobile apps, which allow users to find 7-Eleven - and future Speedway and Stripes - charger locations and pay for charging. 7Charge locations offer CCS and CHAdeMO charging; Tesla drivers, and other vehicles using the (once-proprietary) NACS connector, can also charge, but require a user-supplied CCS adapter. In August 2022, 7-Eleven acquired Skipcart, a same-day and on-demand delivery platform. In early 2024, parent company Seven & i Holdings' CEO Ryuichi Isaka announced changes to the business model of US stores, placing the company's focus on fresh foods instead of a "[reliance] on gasoline and cigarettes".
Sources: en.wikipedia.org
The birds were a food and fuel source for early European settlers, and are now farmed, in Australia and elsewhere, for their meat, oil and leather. Commercial emu farming started in Western Australia around 1970. The commercial industry in the country is based on stock bred in captivity, and all states except Tasmania have licensing requirements to protect wild emus. Outside Australia, emus are farmed on a large scale in North America, with about 1 million birds in the US, Peru, and China, and to a lesser extent in some other countries. Emus breed well in captivity, and are kept in large open pens to avoid the leg and digestive problems that arise from inactivity. They are typically fed on grain supplemented by grazing, and are slaughtered at 15 to 18 months. The Salem district administration in India advised farmers in 2012 not to invest in the emu business which was being heavily promoted at the time; further investigation was needed to assess the profitability of farming the birds in India. In the United States, it was reported in 2013 that many ranchers had left the emu business; it was estimated that the number of growers had dropped from over five thousand in 1998 to one or two thousand in 2013. The remaining growers increasingly rely on sales of oil for their profit, although, leather, eggs, and meat are also sold.
== External links == Mumps Vaccine at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Mumps Vaccine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 28 October 2020. Mumps (The History of Vaccines) Mumps Immunization. WHO
=== Explosion hazard === Dimethyl sulfoxide can produce an explosive reaction when exposed to acyl chlorides; at a low temperature, this reaction produces the oxidant for Swern oxidation.Mancuso, A.J.; Huang, S.L.; Swern, D. (1978). "Oxidation of long-chain and related alcohols to carbonyls by dimethyl sulfoxide "activated" by oxalyl chloride". J. Org. Chem. 43 (12): 2480–2482. doi:10.1021/jo00406a041. DMSO can decompose at the boiling temperature of 189 °C at normal pressure, possibly leading to an explosion. The decomposition is catalyzed by acids and bases and therefore can be relevant at even lower temperatures. A strong to explosive reaction also takes place in combination with halogen compounds, metal nitrides, metal perchlorates, sodium hydride, periodic acid and fluorinating agents.
Sources: en.wikipedia.org
=== Kidney === Nonsteroidal anti-inflammatory drugs "are associated with adverse renal [kidney] effects caused by the reduction in synthesis of renal prostaglandins" in sensitive persons or animal species, and potentially during long-term use in nonsensitive persons if resistance to side effects decreases with age. However, this side effect cannot be avoided merely by using a COX-2 selective inhibitor because, "Both isoforms of COX, COX-1, and COX-2, are expressed in the kidney...
=== Logistics === DHIS2 is used for health logistics data in more than 20 countries in Africa and Asia, where it serves as a last-mile solution for facility-level data capture for health commodities. Most commonly, this involves regular reporting of aggregate data on stocks and usage of common medical supply items such as vaccines, medications, syringes, etc, which facilitates triangulation of health service and commodity data as well as forecasting. In addition, some countries use DHIS2 for vaccine cold chain or other electronic Logistics Management Information System (eLMIS) use cases.
=== Early pumps === The predecessor to the vacuum pump was the suction pump. Dual-action suction pumps were found in the city of Pompeii. The Arab engineer Al-Jazari later described dual-action suction pumps as part of water-raising machines in the 13th century. He also said that a suction pump was used in siphons to discharge Greek fire. The suction pump later appeared in medieval Europe from the 15th century.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.